The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
By Elaine S. Jaffe. Hematology. American Society of Hematology. Education Program, 2009
596 citations recorded by the source corpus.
The 4th edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues published in 2008 builds upon the success of the 2001 3rd edition; new entities are defined, and solutions for problematic categories are sought. Recent studies have drawn attention to the biological overlap between classical Hodgkin lymphoma (CHL) and diffuse large B-cell lymphomas (DLBCL). Similarly, there is a greater appreciation of the borderlands between Burkitt lymphoma and DLBCL. Strategies for the management of these borderline lesions are proposed. Additionally, age-specific and site-specific factors play an important role in the definition of several new entities, which also have biological underpinnings. Among the peripheral T-cell lymphomas (PTCL), more precise definitions were introduced for several entities, including anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, and subcutaneous panniculitis-like T-cell lymphoma. Several new variants of primary cutaneous T-cell lymphomas are proposed. Finally, the subclassification and categorization of the most common lymphoma subtypes, follicular lymphoma (FL) and DLBCL, were altered to enhance diagnostic accuracy and aid in clinical management. The 2008 WHO classification also draws attention to early events in lymphomagenesis. These lesions help delineate the earliest steps in neoplastic transformation and generally mandate a conservative therapeutic approach. The 2001 classification was rapidly adopted for clinical trials and successfully served as a common language for scientists comparing genetic and functional data. The modifications made in the 2008 classification are the result of this successful partnership among pathologists, clinicians, and biologists, but are only a stepping stone to the future.
Subfields: Dermatology, Neurology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/d7270ba3c49dbe4b93cf71f46ed1f84a62d3ab29
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Alexandra G. Smith
- D. Howell
- Eve Roman
- Andrew Jack
- R. Patmore
Citations in the corpus
- TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. (2011, unknown): “More specifically, the natural history of mature T-lymphoid neoplasms is poorly understood (Jaffe, 2009; Jones, 2010).”
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network (2011, background): “…that the rapid rate of progress in understanding tumour biology, and the introduction of new diagnostic technologies and treatments mean WHO classifications, will inevitably require ongoing revision (World Health Organization, 2001; WHO, 2008; Jaffe, 2009; Vardiman et al, 2009; Campo et al, 2011).”